Therma Bright Appoints US Healthcare Veteran Michael Raimondo to the Board of Directors
Therma Bright (OTCQB: TBRIF) announced on October 10, 2025 the appointment of Michael Raimondo to its Board of Directors, elevating him from the advisory board. Raimondo is a 30-year US healthcare sales and operations veteran who the company says has led over $500 million in sales contracts and held senior commercial roles at Abbott.
Raimondo currently serves as Commercial Lead for Delphine Diagnostics and as Managing Partner at The Potentia Group; he said his focus will be building an internal sales team and expanding reseller channels to accelerate sales of Venowave, Therma Bright's flagship medical device. The company also announced the resignation of board member Alex Saringer.
Therma Bright (OTCQB: TBRIF) ha annunciato il 10 ottobre 2025 l'inserimento di Michael Raimondo nel Consiglio di Amministrazione, elevandolo dall advisory board. Raimondo è un veterano statunitense di 30 anni nelle vendite e operazioni sanitarie, che l'azienda dice abbia guidato oltre $500 milioni di contratti di vendita e abbia ricoperto ruoli commerciali senior presso Abbott.
Raimondo è attualmente Responsabile Commerciale per Delphine Diagnostics e Managing Partner presso The Potentia Group; ha detto che il suo obiettivo sarà costruire un team di vendita interno e espandere i canali di rivendita per accelerare le vendite di Venowave, il dispositivo medico di punta di Therma Bright. L'azienda ha anche annunciato le dimissioni del membro del consiglio Alex Saringer.
Therma Bright (OTCQB: TBRIF) anunció el 10 de octubre de 2025 la nombramiento de Michael Raimondo en su Junta Directiva, elevándolo desde la junta asesora. Raimondo es un veterano de 30 años en ventas y operaciones de atención médica en EE. UU., y la empresa dice que ha liderado más de $500 millones en contratos de venta y ha ocupado roles comerciales de alto nivel en Abbott.
Raimondo actualmente se desempeña como Commercial Lead para Delphine Diagnostics y como Socio Managing en The Potentia Group; dijo que su enfoque será construir un equipo de ventas interno y ampliar los canales de revendedor para acelerar las ventas de Venowave, el dispositivo médico insignia de Therma Bright. La empresa también anunció la renuncia del miembro de la junta Alex Saringer.
Therma Bright (OTCQB: TBRIF) 은 2025년 10월 10일 이사회에 Michael Raimondo를 임명했다고 발표했으며, 자문위원회에서 승진했습니다. Raimondo는 미국 보건의료 분야의 30년 경력의 영업 및 운영 전문가로, 회사에 따르면 $500백만의 판매 계약을 주도했고 Abbott에서 수석 상업 직책을 맡아 왔습니다.
Raimondo는 현재 Delphine Diagnostics의 Commercial Lead 및 The Potentia Group의 Managing Partner로 활동하고 있습니다; 그는 Venowave, Therma Bright의 주력 의료기기의 판매를 가속하기 위해 내부 영업팀을 구성하고 재판매 채널을 확장하는 데 집중할 것이라고 밝혔습니다. 또한 회사는 이사회 멤버 Alex Saringer의 사임도 발표했습니다.
Therma Bright (OTCQB: TBRIF) a annoncé le 10 octobre 2025 la nomination de Michael Raimondo au conseil d'administration, le faisant passer du comité consultatif au conseil. Raimondo est un vétéran américain des ventes et des opérations de soins de santé depuis 30 ans qui, selon l'entreprise, a dirigé plus de $500 millions de contrats de vente et occupé des postes commerciaux de haut niveau chez Abbott.
Raimondo occupe actuellement le poste de Commercial Lead chez Delphine Diagnostics et Partner Managing chez The Potentia Group; il a déclaré que son objectif serait de constituer une équipe de vente interne et d'élargir les canaux de revente pour accélérer les ventes de Venowave, le dispositif médical phare de Therma Bright. L'entreprise a également annoncé la démission du membre du conseil Alex Saringer.
Therma Bright (OTCQB: TBRIF) hat am 10. Oktober 2025 die Berufung von Michael Raimondo in den Vorstand bekannt gegeben, der ihn vom Beirat in den Vorstand befördert. Raimondo ist ein 30-jähriger US-amerikanischer Veteran im Gesundheitswesen im Bereich Vertrieb und Betrieb, der das Unternehmen zufolge über $500 Millionen an Verkaufsverträgen geleitet hat und leitende kommerzielle Positionen bei Abbott innehatte.
Raimondo ist derzeit Commercial Lead für Delphine Diagnostics und als Managing Partner bei The Potentia Group tätig; er sagte, sein Fokus werde darauf liegen, ein internes Vertriebsteam aufzubauen und Wiederverkäuferkanäle zu erweitern, um den Verkauf von Venowave, Therma Brights Flaggschiff-Medizinprodukt, zu beschleunigen. Das Unternehmen kündigte außerdem den Rücktritt des Vorstandsmitglieds Alex Saringer an.
Therma Bright (OTCQB: TBRIF) أعلن عن 10 أكتوبر 2025 تعيين Michael Raimondo في مجلس الإدارة، رفعه من المجلس الاستشاري. Raimondo هو مخضرم في مبيعات وعمليات الرعاية الصحية في الولايات المتحدة لمدة 30 عامًا، وتقول الشركة إنه قاد أكثر من $500 مليون من عقود المبيعات وتولى مناصب تجارية عليا في Abbott.
يقّدم Raimondo حالياً كقائد تجاري لـ Delphine Diagnostics وكشريك إداري في The Potentia Group؛ قال إن تركيزه سيكون بناء فريق مبيعات داخلي وتوسيع قنوات إعادة البيع لتسريع مبيعات Venowave، الجهاز الطبي الرائد لشركة Therma Bright. كما أعلنت الشركة عن استقالة عضو المجلس Alex Saringer.
Therma Bright (OTCQB: TBRIF) 在 2025年10月10日 发布了将 Michael Raimondo 任命为董事会成员的消息，使他从顾问委员会升任董事会成员。Raimondo 是一位在美国拥有 30 年医疗保健销售和运营经验的资深人士，公司称他曾领导超过 $500 百万 的销售合同，并在 Abbott 担任高级商业职务。
Raimondo 目前担任 Delphine Diagnostics 的 Commercial Lead，以及 The Potentia Group 的 Managing Partner；他表示，重点将放在建立内部销售团队和扩大再销售渠道，以加速 Venowave——Therma Bright 的旗舰医疗设备的销售。公司还宣布董事会成员 Alex Saringer 辭任。
- Board appointment of Michael Raimondo on October 10, 2025
- Raimondo credited with driving over $500 million in sales contracts
- Immediate commercial focus to scale Venowave via internal sales team and reseller channels
- None.
Toronto, Ontario--(Newsfile Corp. - October 10, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner in advanced diagnostic and medical device technologies, is pleased to announce the appointment of Michael Raimondo, a 30-year veteran in sales and operations in the healthcare industry to its Board of Directors. Michael was part of Therma's advisory Board, previously announced on August 13, 2024.
Mr. Raimondo is a distinguished executive and strategist known for his extensive commercial leadership experience in the healthcare and business services sectors across the USA. Mr. Raimondo specializes in sales negotiations, which has successfully led to over
He is a retired veteran of the global healthcare industry, having concluded a successful tenure at Abbott, where he held significant senior leadership positions focusing on commercial strategy and business development.
Following his career at Abbott, Mr. Raimondo transitioned into key advisory and executive roles across various organizations. He currently serves as the Commercial Lead for Delphine Diagnostics in New Jersey (NJ), where he drives market strategy and business growth.
Demonstrating his broad expertise, he also serves as a Managing Partner at The Potentia Group, which specializes in negotiations training, sales leadership development and consulting within the U.S. healthcare market. Michael is an active member of the board for Marketsmith one of the largest woman-owned and operated independent media and marketing agencies in the USA. Michael has a BS in physics and minor in mathematics from Kutztown University, and has served on the board of the Make A Wish Foundation for the Ohio-Kentucky-Indiana region.
Rob Fia, CEO, commented, "We are excited to announce that Michael is joining us in a strategic role, transitioning from Advisory Board Member to full Board Member, where we will fully utilize his extensive commercial expertise. Michael's deep industry knowledge will assist Therma Bright to accelerate market penetration and to drive sales growth of Venowave, our flagship medical device."
Michael Raimondo commented: "I am pleased to be joining the Board and contributing to the significant growth potential of the Venowave platform. My primary focus will be on leveraging my commercial experience to rapidly scale the organization-specifically by designing and implementing a high-performance, results-driven internal sales team. Simultaneously, I look forward to enhancing our market reach by expanding our channels through strategic partnerships with high-value medical device resellers, ensuring Venowave reaches patients suffering from vascular issues, such as the 900,000 citizens who suffer from deep vein thrombosis each year per the US CDC."
Therma Bright announces the resignation of Board member Alex Saringer. The Company would like to thank Alex for his service.
About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0). Visit: www.thermabright.com.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events and related information such as future sales of Venowave as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-Looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269945
FAQ
Who did Therma Bright (TBRIF) appoint to its board on October 10, 2025?
What experience does Michael Raimondo bring to Therma Bright (TBRIF)?
How will Michael Raimondo support Venowave commercialization for TBRIF?
Did Therma Bright (TBRIF) announce any board departures on October 10, 2025?
What current roles does Michael Raimondo hold that relate to his new TBRIF board position?
Does Michael Raimondo plan to target a specific patient population with Venowave for TBRIF?
